Good morning, everyone, and welcome to another working week. Those of you on our side of the pond had, of course, an extended respite thanks to a federal holiday, and we hope your time was relaxing and invigorating, because that oh-so-familiar routine of deadlines, meetings, and the like has now returned. There is only one thing to do in such situations: reach for a cup of stimulation. Our choice today is macadamia nut. Feel free to join us with whatever flavor you prefer. Or perhaps a spot of tea is in order. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Hope you have a smashing day and do keep in touch …

An AstraZeneca (AZN) immunotherapy won approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors, Reuters tells us. Known as Imfinzi, the drug will be given to non-small cell lung cancer patients with inoperable mid-stage disease that has not spread widely, the first immunotherapy to be approved in this setting. The endorsement gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy